Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Altra Industrial Motion

Aramark

Bowlero Corp

Salesforce

First Horizon National

Alphabet

iShares iBoxx $ Investment Grade Corporate Bond ETF

Rivian Automotive

One of Soros' top 10 holdings looks especially attractive right now.

Nearly One-Third of Billionaire George Soros' Portfolio Is Invested in These 10 Stocks

Amgen

VanEck Vectors Biotech ETF

Biogen

Gilead Sciences

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

The latest earnings from some of the big biotech players came in at mixed this reporting season.

How Are Biotech ETFs Reacting to Q4 Earnings Releases?

Two billionaires –Paul Tudor Jones and George Soros — acquired shares of Horizon Therapeutics (NASDAQ: HZNP ) stock, a drugmaker, last quarter. On Dec. 12, Horizon agreed to be acquired by a giant pharmaceutical company, Amgen (NASDAQ: AMGN ).

Why Billionaires Paul Tudor Jones and George Soros Bought Up Horizon (HZNP) Stock

Bank of America

Paramount Global

Billionaire-led investing firms scooped up shares of Paramount Global, Bank of America, and Horizon Therapeutics in Q4.

Billionaires Loaded Up on These 3 Stocks in the Fourth Quarter of 2022

Biotechnology giant Amgen Inc. began talks with investors on Tuesday about a potential jumbo bond deal to help finance its roughly $28 billion acquisition of Dublin-based Horizon Therapeutics, according to the company, investors, analysts and deal documents.

Amgen plans mega bond deal to help fund $28 billion Horizon Therapeutics acquisition

Soros Fund Management, the family office of billionaire George Soros, added to its portfolio new shares in financial and healthcare companies and a bonds exchanged-traded fund in the fourth quarter, according to a regulatory filing on Monday.

Soros Fund adds First Horizon, Horizon Therapeutics and bond ETF

Opiant Pharmaceuticals

Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals.

Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Horizon Therapeutics Public Limited Company (NasdaqGS: HZNP) to Amgen Inc. (NasdaqGS: AMGN). Under the terms of the proposed transaction, shareholders of Horizon will receive only $116.50 in cash for each share of Horizon that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

HORIZON THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limited Company - HZNP

Horizon Therapeutics (HZNP) announces that a phase II Sjogren's syndrome study of its candidate, dazodalibep, meets the primary endpoint for the second population.

Horizon (HZNP) Dazodalibep Meets Goal in Sjogren's Syndrome Study

Repligen

HZNP vs. RGEN: Which Stock Is the Better Value Option?

AbbVie

BioNTech SE

CSL Ltd

Moderna

Pfizer

Vertex Pharmaceuticals

The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment insights.

Ranking The 10 Largest Biotechs By Pipeline

Bristol-Myers

Eli Lilly

Merck

Not every stock went down in 2022. Shares in some the biggest pharmaceutical companies rose in price.

5 Top Pharma Stocks of 2022 to Buy for the Long Haul

Agnico Eagle Mines

APA Corporation

Anglogold Ashanti Plc

Bausch Health Companies Inc

BrightSphere Investment Group

Perpetua Resources Corp

SSR Mining

John Paulson is the founder, president and portfolio manager at Paulson & Co.

These Are The Top 10 Holdings Of John Paulson

If you need an "end-of-the-year stock, here are three reasons why Horizon Therapeutics could be an outstanding stock to consider.

Horizon Therapeutics: A Strong Stock to End 2022

DUBLIN--( BUSINESS WIRE )--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+. This rare autoimmune disease is caused by inflammation in the central nervous system, resulting in severe and recurrent attacks that can lead to permanent disability, such as paralysis and vision loss.1 An estimated 10,000 people in Brazil live with the disease.2

UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Coupa Software

iStar

UserTesting

NEW YORK , Dec. 20, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: iStar Inc. (NYSE: STAR)'s  merger with Safehold Inc. If you are an iStar shareholder, click here to learn more about your rights and options .   Horizon Therapeutics plc (NASDAQ: HZNP)'s  sale to Amgen Inc. for $116.50 in cash per share.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAR, HZNP, COUP, USER

Amgen Inc. ( AMGN , Financial) shook up the market on Monday when the company announced it had agreed to purchase Horizon Therapeutics PLC ( HZNP , Financial) for $27.8 billion.

How Horizon Therapeutics Will Strengthen Amgen's Portfolio

HORIZON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limited Company - HZNP

Biotech giant Amgen Inc. ( AMGN , Financial) is on a mission to meet unmet medical needs while generating solid returns for investors. As part of this strategy, the company has recently been taking advantage of lower stock valuations to make attractive buyout offers for biotech players with promising treatments.

Horizon Jumps 15% on $26 Billion Acquisition Deal

New York, New York--(Newsfile Corp. - December 13, 2022) - Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Horizon Therapeutics Public Limited Co. (NASDAQ: HZNP), relating to its proposed acquisition by Amgen, Inc.

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Horizon Therapeutics Public Limited Co. - HZNP

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

SPDR S&P Pharmaceuticals ETF

Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.

Amgen to Buy Horizon Therapeutics: ETFs to Bet On

Oracle

Boeing

So far this week, several stocks have had headline-driven catalysts. We will cover 5 stocks trending in the news.

Trending Today: 5 Stocks in the News

Amgen has become the winner in the Horizon Therapeutics sale process. The deal comes at a full price, offset by synergy estimates and pipeline additions.

Amgen: 'Winner' For Horizon

NEW YORK , Dec. 12, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Horizon Therapeutics Public Limited Company ("Horizon Therapeutics" or the "Company") (NASDAQ: HZNP) in connection with the proposed acquisition of the Company by Amgen Inc. (NASDAQ: AMGN).  Under the terms of the merger agreement, the Company's shareholders will receive $116.50 in cash for each share of Horizon Therapeutics common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Horizon Therapeutics Public Limited Company

The purchase of Horizon Therapeutics is the biggest this year by a major drugmaker seeking new sources of revenue to offset impending patent expiries.

Amgen Hunts for New Revenue in $28 Billion Deal

News for Horizon Pharma Stock (HZNP)